FDA approves obecabtagene autoleucel for acute lymphoblastic leukemia
On November 8, 2024, the FDA approved obecabtagene autoleucel (Aucatzyl, Autolus Inc.) for relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Related Articles
HOPE-PMF Trial Set to Investigate Interferon-Based Therapy for Early and Low-Risk PMF | Blood Cancers Today
The soon-opening phase 3 HOPE-PMF trial will investigate the efficacy of interferon-based therapy, ropeginterferon alfa-2b (ropeg), for early and lower-risk primary myelofibrosis.
Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers
Sotorasib and other selected KRASG12C inhibitors leverage differential dependence on switch-II pocket binding at amino acid position 95 to target all RASG12C isoforms, which has…
SurgOnc Today® – Society of Surgical Oncology
SurgOnc Today® is an educational podcast for cancer surgeons from the Society of Surgical Oncology. Each episode features conversations with individuals who are experts within their…
OCE Conversations on Cancer – Cervical Cancer Treatment Innovation: A Collaborative Discussion
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Cancer of the Liver and Intrahepatic Bile Duct – Cancer Stat Facts
Liver and Intrahepatic Bile Duct Cancer statistics
FDA Broad Agency Announcement: Frequently Asked Questions for Oncology
FDA Broad Agency Announcement: Frequently Asked Questions for Oncology Researchers
Call for Papers | Cancer Research | American Association for Cancer Research
Call for Papers | Cancer Research | American Association for Cancer Research .aacrcontent ul {list-style-image: url(‘/ImageLibrary/CR/icons/cr_bullet.png’);} .banner{ display: block; width: 100% margin: -20px; } .banner-sm{…
FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injecti
FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection
Ways to Help
Join the Lymphoma Research Foundation to help raise awareness and funds for lymphoma research and education through its volunteer and fundraising programs
NCCR*Explorer Application
Use NCCR*Explorer to select data characteristics including cancer site, incidence or survival, sex, race/ethnicity, and age groups (0-39) to display incidence rates, trends over time,…